ALNY vs. ZBH: A Head-to-Head Stock Comparison

Updated on July 8, 2025

Here’s a clear look at ALNY and ZBH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ALNY’s market capitalization of 43.28 billion USD is substantially larger than ZBH’s 18.53 billion USD, indicating a significant difference in their market valuations.

ZBH carries a higher beta at 0.72, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.

Symbol	ALNY	ZBH
Company Name	Alnylam Pharmaceuticals, Inc.	Zimmer Biomet Holdings, Inc.
Country	US	US
Sector	Healthcare	Healthcare
Industry	Biotechnology	Medical - Devices
CEO	Yvonne L. Greenstreet	Ivan Tornos
Price	331.91 USD	93.67 USD
Market Cap	43.28 billion USD	18.53 billion USD
Beta	0.21	0.72
Exchange	NASDAQ	NYSE
IPO Date	June 1, 2004	July 25, 2001
ADR	No	No

Historical Performance

This chart compares the performance of ALNY and ZBH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALNY vs. ZBH: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALNY

-509.33%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ZBH

7.31%

Medical - Devices Industry

Max: 49.04%
Q3: 9.53%
Median: -7.46%
Q1: -32.83%
Min: -82.64%

ZBH’s Return on Equity of 7.31% is on par with the norm for the Medical - Devices industry, indicating its profitability relative to shareholder equity is typical for the sector.

ALNY vs. ZBH: A comparison of their ROE against their respective Biotechnology and Medical - Devices industry benchmarks.

Return on Invested Capital

ALNY

-2.79%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ZBH

5.58%

Medical - Devices Industry

Max: 21.88%
Q3: 6.63%
Median: -1.11%
Q1: -21.08%
Min: -51.95%

ZBH’s Return on Invested Capital of 5.58% is in line with the norm for the Medical - Devices industry, reflecting a standard level of efficiency in generating profits from its capital base.

ALNY vs. ZBH: A comparison of their ROIC against their respective Biotechnology and Medical - Devices industry benchmarks.

Net Profit Margin

ALNY

-11.49%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ZBH

11.86%

Medical - Devices Industry

Max: 44.80%
Q3: 9.77%
Median: -5.53%
Q1: -29.37%
Min: -87.68%

A Net Profit Margin of 11.86% places ZBH in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.

ALNY vs. ZBH: A comparison of their Net Profit Margin against their respective Biotechnology and Medical - Devices industry benchmarks.

Operating Profit Margin

ALNY

-4.91%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ZBH

17.04%

Medical - Devices Industry

Max: 30.13%
Q3: 13.12%
Median: 3.47%
Q1: -24.42%
Min: -80.56%

An Operating Profit Margin of 17.04% places ZBH in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ALNY vs. ZBH: A comparison of their Operating Margin against their respective Biotechnology and Medical - Devices industry benchmarks.

Profitability at a Glance

Symbol	ALNY	ZBH
Return on Equity (TTM)	-509.33%	7.31%
Return on Assets (TTM)	-6.40%	4.12%
Return on Invested Capital (TTM)	-2.79%	5.58%
Net Profit Margin (TTM)	-11.49%	11.86%
Operating Profit Margin (TTM)	-4.91%	17.04%
Gross Profit Margin (TTM)	86.01%	71.05%

Financial Strength

Current Ratio

ALNY

3.04

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ZBH

2.44

Medical - Devices Industry

Max: 12.68
Q3: 6.30
Median: 4.05
Q1: 1.85
Min: 0.01

ZBH’s Current Ratio of 2.44 aligns with the median group of the Medical - Devices industry, indicating that its short-term liquidity is in line with its sector peers.

ALNY vs. ZBH: A comparison of their Current Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Debt-to-Equity Ratio

ALNY

11.28

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

ZBH

0.58

Medical - Devices Industry

Max: 2.34
Q3: 1.09
Median: 0.37
Q1: 0.08
Min: 0.00

ZBH’s Debt-to-Equity Ratio of 0.58 is typical for the Medical - Devices industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALNY vs. ZBH: A comparison of their D/E Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Interest Coverage Ratio

ALNY

-0.79

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ZBH

5.62

Medical - Devices Industry

Max: 18.18
Q3: 7.53
Median: 0.85
Q1: -9.80
Min: -33.94

ZBH’s Interest Coverage Ratio of 5.62 is positioned comfortably within the norm for the Medical - Devices industry, indicating a standard and healthy capacity to cover its interest payments.

ALNY vs. ZBH: A comparison of their Interest Coverage against their respective Biotechnology and Medical - Devices industry benchmarks.

Financial Strength at a Glance

Symbol	ALNY	ZBH
Current Ratio (TTM)	3.04	2.44
Quick Ratio (TTM)	2.98	1.46
Debt-to-Equity Ratio (TTM)	11.28	0.58
Debt-to-Asset Ratio (TTM)	0.31	0.32
Net Debt-to-EBITDA Ratio (TTM)	-1.85	2.52
Interest Coverage Ratio (TTM)	-0.79	5.62

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALNY and ZBH. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALNY vs. ZBH: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALNY vs. ZBH: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALNY vs. ZBH: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ZBH

1.02%

Medical - Devices Industry

Max: 3.57%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 1.02%, ZBH offers a more attractive income stream than most of its peers in the Medical - Devices industry, signaling a strong commitment to shareholder returns.

ALNY vs. ZBH: A comparison of their Dividend Yield against their respective Biotechnology and Medical - Devices industry benchmarks.

Dividend Payout Ratio

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ZBH

21.28%

Medical - Devices Industry

Max: 102.12%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZBH’s Dividend Payout Ratio of 21.28% is in the upper quartile for the Medical - Devices industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

ALNY vs. ZBH: A comparison of their Payout Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Dividend at a Glance

Symbol	ALNY	ZBH
Dividend Yield (TTM)	0.00%	1.02%
Dividend Payout Ratio (TTM)	0.00%	21.28%

Valuation

Price-to-Earnings Ratio

ALNY

-159.59

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ZBH

20.40

Medical - Devices Industry

Max: 90.56
Q3: 56.92
Median: 43.19
Q1: 21.79
Min: 5.55

In the lower quartile for the Medical - Devices industry, ZBH’s P/E Ratio of 20.40 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

ALNY vs. ZBH: A comparison of their P/E Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Forward P/E to Growth Ratio

ALNY

-43.29

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

ZBH

2.73

Medical - Devices Industry

Max: 6.56
Q3: 3.52
Median: 2.22
Q1: 0.55
Min: 0.03

ZBH’s Forward PEG Ratio of 2.73 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

ALNY vs. ZBH: A comparison of their Forward PEG Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Price-to-Sales Ratio

ALNY

18.43

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ZBH

2.41

Medical - Devices Industry

Max: 15.74
Q3: 8.12
Median: 3.40
Q1: 2.37
Min: 0.42

ZBH’s P/S Ratio of 2.41 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALNY vs. ZBH: A comparison of their P/S Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Price-to-Book Ratio

ALNY

372.86

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ZBH

1.50

Medical - Devices Industry

Max: 16.65
Q3: 8.03
Median: 3.73
Q1: 1.92
Min: 0.65

ZBH’s P/B Ratio of 1.50 is in the lower quartile for the Medical - Devices industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ALNY vs. ZBH: A comparison of their P/B Ratio against their respective Biotechnology and Medical - Devices industry benchmarks.

Valuation at a Glance

Symbol	ALNY	ZBH
Price-to-Earnings Ratio (P/E, TTM)	-159.59	20.40
Forward PEG Ratio (TTM)	-43.29	2.73
Price-to-Sales Ratio (P/S, TTM)	18.43	2.41
Price-to-Book Ratio (P/B, TTM)	372.86	1.50
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	-574.08	13.74
EV-to-EBITDA (TTM)	-285.32	10.59
EV-to-Sales (TTM)	18.55	3.16